96 results about "Immunoglobulin region" patented technology

The invention relates to a novel coronavirus SARS-CoV-2 mutant vaccine and application, the vaccine comprises a fusion protein, and the fusion protein comprises: (1) interferon or a functional fragment thereof; (2) a novel coronavirus SARS-CoV-2Omicron mutant strain S protein or a functional fragment of the novel coronavirus SARS-CoV-2Omicron mutant strain S protein; and (3) an immunoglobulin Fc region. Molecule and process optimization of the fusion protein comprises improvement of process developability and immunogenicity, and the vaccine can improve immunogenicity and antibody titer of a mutant new crown antigen through convergence mutation design, efficiently generate a neutralizing antibody, significantly improve defense ability to a variant strain, and can be massively and industrially produced.

Chimeric antigen receptors that include an antigen recognition domain; a spacer domain derived from a modified immunoglobulin Fc region having one or more mutations in its CH2 region resulting in impaired binding to an FcR; and an intracellular signaling domain.

The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human BCMA and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof bind to a human Fc-γ receptor.The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including multiple myeloma (MM).

This disclosure provides a method of preventing, alleviating, or treating a condition (i.e., neutropenia) in a patient in need thereof, the condition characterized by compromised white blood cell production in the patient. The method includes administering to the patient a therapeutically effective amount of a protein complex comprising a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer. The non-peptidyl polymer is site-specifically linked to an N-terminus of the immunoglobulin Fc region, and the modified hG-CSF comprises substitutions in at least one of Cys17 and Pro65.

The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human BCMA and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof bind to a human Fc-γ receptor.The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including multiple myeloma (MM).

Provided are an immunoglobulin Fc region having reduced binding capacity to FcRn, a fusion protein comprising the same, a nucleic acid encoding the same, and a vector and a cell comprising the nucleic acid.

This disclosure provides a method of preventing, alleviating, or treating a condition (i.e., neutropenia) in a patient in need thereof, the condition characterized by compromised white blood cell production in the patient. The method includes administering to the patient a therapeutically effective amount of a protein complex comprising a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer at a fixed dose regardless of the patient's weight.

The invention relates to the field of antibody proteins, in particular to an immunoglobulin Fc dimer with a stable disulfide bond, an Fc fusion protein containing the Fc protein dimer and a calculation design method of the Fc fusion protein. The immunoglobulin Fc protein dimer comprises two protein subunits, a CH3 structural domain of each subunit contains at least one cysteine mutation, and the two protein subunits are combined through an interchain disulfide bond formed by mutation cysteine. Cysteine mutation is specifically introduced into the CH3 structural domain of the Fc region of the immunoglobulin to form a stable interchain disulfide bond, so that the problem of insufficient stability of the Fc protein dimer is solved.

The present invention relates to a multispecific antibody comprising one or two binding domains, which specifically bind to IL-4R (IL4R-BDs), and one or two binding domains, which specifically bind to IL-31 (IL31-BDs), wherein the multispecific antibody comprises an immunoglobulin Fc region. The present invention further relates to nucleic acids encoding said multispecific antibody, vector(s) comprising said nucleic acids, host cell(s) comprising said nucleic acids or said vector(s), and a method of producing said multispecific antibody. Additionally, the present invention relates to pharmaceutical compositions comprising said multispecific antibody and methods of use thereof.

Provided is a complex composition, of which positional isomers are minimized by using a N-terminus of an immunoglobulin Fc region as a binding site when the immunoglobulin Fc region is used as a carrier. Also provided are a protein complex which is prepared by N-terminal-specific binding of immunoglobulin Fc region, thereby prolonging blood half-life of the physiologically active polypeptide, maintaining in vivo potency at a high level, and having no risk of immune responses, a preparation method thereof, and a pharmaceutical composition including the same for improving in vivo duration and stability of the physiologically active polypeptide. The protein complex may be usefully applied to the development of long-acting formulations of various physiologically active polypeptide drugs.

The present invention describes engineered immunoglobulin IgG Fc regions by transferring structural elements, several CH2 inter-chain disulfide bonds, from IgA to IgG immunoglobulin. The disclosed Fc variants created thereof exhibit marked reductions or complete abrogation of interaction of the engineered Fc with FcγR and C1q while retaining natural ability to interact with FcRn at acidic pH. Silenced Fc molecules disclosed are in comparable expression and purification yields and improved or maintained thermostability compared to wild-type Fc, thereby limiting the propensity for aggregation. In addition, the disclosed Fc variant silencing mutations are capable of reducing or compensating destabilizing effects of other half-life extending or chain pairing facilitating Fc mutations.

Provided are an immunoglobulin Fc region-based heterodimeric Fc stent, a heterologous multimeric protein containing the heterodimeric Fc stent, in particular a single or multispecific binding protein, and a composition comprising same and a use.

The present invention relates to a fusion protein comprising GLP-1, immunoglobulin Fc region, and IGF-1, and use thereof. The fusion protein of the present invention has excellent efficiency in blood-brain barrier permeability, and thus can be widely used for the effective treatment of neurological diseases.

The name of the invention is a composition for treating diabetes mellitus comprising insulin and a GLP-1 / glucagon dual agonist. The present invention relates to a composition for preventing or treating diabetes mellitus comprising insulin and a GLP-1 / glucagon dual agonist, and a method for preventing or treating diabetes mellitus. More specifically, by administering a long-acting insulin conjugate and a long-acting GLP-1 / glucagon dual agonist conjugate in combination, the present composition can inhibit weight gain and reduce the risk of hypoglycemia due to administration of insulin, reduce the dosage of administration, and greatly improve the compliance of a drug. Further, since insulin and a GLP-1 / glucagon dual agonist are linked to an immunoglobulin Fc region via a non-peptidyl linker, the long-acting insulin conjugate and the long-acting GLP-1 / glucagon dual agonist conjugate according to the present invention can improve in vivo persistence and stability.

The application discloses a VirusTAC platform for targeted degradation of tumor cell membrane protein EGFR and psoriasis extracellular pathogenic factor IL17A and application thereof, and belongs to the technical field of biological medicines. The platform comprises a heterodimer with R1-R2-R3 structure formed by a first polypeptide chain and a second polypeptide chain, wherein R1 is MeV H or a variant thereof; R2 is a linker composed of R4 and R5, R4 is an immunoglobulin Fc region, the Fc regions corresponding to the first polypeptide chain and the second polypeptide chain are associated by heterodimerization mutation; R5 is a linker that can be cut by a protease; and R3 is a target protein binding domain EGFR antibody or IL17A antibody. The platform realizes precise degradation of tumor-related membrane proteins and extracellular proteins by constructing a chimera of a natural ligand and a targeting antibody, and by means of tumor-specific expression and efficient endocytosis characteristics of Nectin-4.

The purpose of the present invention is to provide a novel HVEM-binding protein. The present invention provides a human HVEM-binding protein comprising at least one immunoglobulin single variable region, wherein: the immunoglobulin single variable region includes complementarity determining regions 1-3 which have the amino acid sequence of SEQ ID NO: 1, the amino acid sequence of SEQ ID NO: 2, and the amino acid sequence of SEQ ID NO: 3, respectively; and the immunoglobulin single variable region is a humanized VHH. The protein according to the present invention may further comprise a human immunoglobulin Fc region or a human serum albumin-binding protein, and the immunoglobulin Fc region may be an Fc region of human IgG4.

The present application relates to an immunoglobulin which has an Fc region as shown in SEQ ID NO: 1. The immunoglobulin can self-polymerize monomers into a stable polymer structure, and has improved titer, detection sensitivity or correlation when being used for detection.

This disclosure provides a method of preventing, alleviating or treating a condition (i.e., neutropenia) in a subject in need thereof, the condition characterized by compromised white blood cell production in the subject. The method includes administering to the subject a therapeutically effective amount of a protein complex on the same day as a chemotherapy regimen, wherein the protein complex is a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer. The non-peptidyl polymer is site-specifically linked to an N-terminus of the immunoglobulin Fc region, and the modified hG-CSF comprises substitutions in at least one of Cys17 and Pro65.

Methods and compositions for generating novel proteins comprise a genetically encoded macrocyclic peptide fused to an immunoglobulin Fc region, referred to as “cyclopeptibodies.” Methods and compositions are provided for making cyclopeptide-Fc region fusion proteins from genetically encoded, ribosomally produced artificial polypeptides. These methods are based on the genetic fusion of an immunoglobulin Fc region to an artificial precursor polypeptide comprising a non-canonical amino acid residue carrying a thiol-reactive functional group; and a cysteine residue that is positioned either upstream or downstream of the non-canonical amino acid in the polypeptide sequence. These methods are based on the ability of the functional group-bearing amino acid and cysteine residue to react after ribosomal synthesis of the polypeptide, so that a cyclic peptide carrying a side-chain-to-side-chain covalent (thioether) linkage is formed and that thioether-linked cyclic peptide is genetically fused to the Fc region of an immunoglobulin.

The invention provides a preparation method of a recombinant protein for improving retinal oxidative stress. The recombinant protein comprises an immunoglobulin Fc region and a functional structure domain, and the amino acid sequence of the functional structure domain is as shown in SEQ ID NO. 1. The preparation method comprises the following steps: connecting polynucleotide for coding the recombinant protein to an expression vector to construct a recombinant expression vector; and transferring the recombinant expression vector into an expression cell, and carrying out induced expression, separation and purification to obtain the recombinant protein. According to the preparation method, the recombinant protein with high soluble expression and enhanced stability can be obtained.

The present disclosure relates to a novel coronavirus SARS-CoV-2 mutant vaccine and its application, the vaccine comprising a fusion protein comprising: (1) interferon or a functional fragment thereof; (2) novel coronavirus SARS-CoV-2 or a functional fragment thereof; and (3) an immunoglobulin Fc region. The mutant vaccine disclosed herein has long-lasting efficacy, is amenable to industrial production, has activity comparable to that of conventional IFN, has higher immunogenicity and neutralizing antibody titers, and can increase defense against mutant strains. It can be used as a new generation of mutant vaccine drugs to combat the spread of the COVID-19 pandemic.

A fusion protein of a dimeric therapeutic enzyme and an immunoglobulin Fc region, a preparation method thereof, and a composition containing the fusion protein are disclosed.

Provided herein are methods for treating or preventing leukemia and myelodysplasia disorders comprising a multifunctional binding protein comprising a first antigen-binding domain and a second antigen-binding domain and all or part of an immunoglobulin Fc region or variant thereof wherein the first antigen-binding domain specifically binds to CD123, and the second antigen-binding domain specifically binds to CD123, and all or part of an immunoglobulin Fc region or variant thereof. And the second antigen-binding domain specifically binds to human NKp46, and wherein all or part of the immunoglobulin Fc region or variant thereof binds to a human Fc-gamma receptor.

Provided are proteins comprising a variant IgG Fc region, wherein the proteins exhibit significantly reduced binding to human FcγRI when compared with a reference protein comprising the amino acid substitutions L234A / L235A / P329G. Also provided are compositions, methods of treatment and methods to reduce Fc-induced effector functions in a parent protein.

The present invention relates to a pharmaceutical composition comprising an immunoglobulin Fc region and an IL-7 fusion protein. Specifically, when a fusion protein comprising the immunoglobulin Fc region and IL-7 is administered to an affected area, a strong immune response is induced in the body and thus allows human papillomavirus-caused diseases to be prevented or treated.

The present application relates to a fusion protein and use thereof. The fusion protein comprises a human GLP-1 polypeptide variant and an immunoglobulin Fc region, wherein an amino acid sequence of the human GLP-1 polypeptide variant comprises at least 2 amino acid mutations compared with an amino acid sequence set forth in SEQ ID NO: 2, and the at least 2 amino acid mutations are located at amino acid positions selected from the group consisting of W31, K26, and Y19. The present application also provides use of the fusion protein in treating a disease or a condition.

Provided are PD-1 polypeptide variants including an extracellular domain that binds specifically to PD-L1, and a transmembrane domain or a fragment thereof. The disclosure also provides PD-1 Fc fusion proteins including an immunoglobulin Fc region, and a PD-1 polypeptide variant.

The current invention is directed to an antibody comprising at least four binding sites specifically binding to an immunoglobulin Fc-region of the human IgG1 subclass comprising one, two, three or four amino acid changes compared to a wild-type Fc-region of the human IgG1 subclass for use as positive control and calibration standard in an immunoassay for the detection and quantification of anti-drug antibodies against said one, two, three or four amino acid changes in the Fc-region of the drug antibody.

Provided is an adapter comprising an antibody binding domain (AbBD) that specifically binds and crosslinks to an immunoglobulin Fab region, where the AbBD is a variant of a Protein A domain D and has an amino acid replacement / modification at A28, G32, Q35, S36, N46, G49, E50, K53 or L54 of SEQ ID NO: 1 or combinations thereof, and where the AbBD is photoreactive. Also provided is an adapter comprising an AbBD that specifically binds and crosslinks to an IgG Fab region and / or to an immunoglobulin M (IgM) Fab region, where the AbBD is a variant of a Protein A domain D and has an amino acid replacement / modification at A28, E50, or L54 of SEQ ID NO: 1 or combinations thereof, where the AbBD is photoreactive. Provided is an adapter comprising an AbBD that specifically binds and crosslinks to an IgG Fab region, where the AbBD is a variant of a Protein L C* domain and has an amino acid replacement / modification at G22 or T46 of SEQ ID NO: 2 or a combination thereof, wherein the AbBD is photo-reactive. Methods for using the AbBD for imaging, diagnosing and / or treating a disease are provided.